Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 12/20 | 1.00 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Candoxatril SCHEMBL29494166 | 1.00 | MME (1.00) | MMEPPARGPPARDKDM4EPPARA | |
| Candoxatril SCHEMBL392920 | 1.00 | MME (1.00) | MMEPPARGPPARDKDM4EPPARA | |
| Candoxatril SCHEMBL1649937 | 1.00 | MME (1.00) | MMEPPARGPPARDKDM4EPPARA | |
| Candoxatril SCHEMBL5601069 | 1.00 | MME (1.00) | MMEPPARGPPARDKDM4EPPARA | |
| Candoxatril SCHEMBL14660450 | 0.98 | MME (0.95) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL9470376 | 0.94 | MME (0.88) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL16624679 | 0.92 | MME (0.85) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL7322664 | 0.91 | MME (0.83) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL7329974 | 0.91 | MME (0.83) | MMEPPARGPPARDKDM4EPPARA | |
| SCHEMBL9469895 | 0.89 | MME (0.80) | MMEPPARGPPARDKDM4EPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2141 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4595974-A2 | THERAPEUTIC COMBINATIONS OF TDFRPS AND ADDITIONAL AGENTS AND METHODS OF USE | Carlson, William D. (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250191770-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | PFIZER INC. (US) | 2025-06-12 | — | — | US | claimed |
| US-20240123033-A1 | THERAPEUTIC COMBINATIONS OF TDFRPs AND ADDITIONAL AGENTS AND METHODS OF USE FOR THE REVERSAL OF FIBROSIS | Therapeutics By Design, LLC (US) | 2024-04-18 | — | — | US | claimed |
| EP-4308587-A1 | THERAPEUTIC COMBINATIONS OF TDFRPS AND ADDITIONAL AGENTS AND METHODS OF USE FOR THE REVERSAL OF FIBROSIS | Therapeutics by Design, LLC (US) | 2024-01-24 | — | — | EP | claimed |
| US-20230338385-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-10-26 | — | — | US | claimed |
| US-20230329630-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | PFIZER INC. (US) | 2023-10-19 | — | — | US | claimed |
| US-11759465-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-09-19 | — | — | US | claimed |
| WO-2023166453-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | PFIZER INC. (US) | 2023-09-07 | — | — | WO | claimed |
| EP-4203775-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | Pfizer Inc. (US) | 2023-07-05 | — | — | EP | claimed |
| US-20030050301-A1 | Combination of aldose reductase inhibitors and angiotensin-II antagonists for the treatment of diabetic nephropathy | MYLARI BANAVARA L (US) | 2003-03-13 | — | — | US | claimed |
| WO-2002074234-A2 | METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS | PROCHON BIOTECH LTD. (IL) | 2002-09-26 | — | — | WO | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| US-20020068740-A1 | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications | MYLARI BANAVARA L (US) | 2002-06-06 | — | — | US | claimed |
| EP-1106210-A2 | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications | Pfizer Products Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| US-5192800-A | Hypotensive agents | PFIZER INC. (US) | 1993-03-09 | — | — | US | claimed |
| EP-0342850-B1 | ENANTIOMERIC GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1992-05-20 | — | — | EP | claimed |
| US-5030654-A | Glutaramide diuretic agents | PFIZER INC. (US) | 1991-07-09 | — | — | US | claimed |
| EP-0342850-A1 | Enantiomeric glutaramide diuretic agents | Pfizer Limited (GB) | 1989-11-23 | — | — | EP | claimed |